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We characterized the expression of Epstein–Barr virus (EBV) on two epithelial cell lines, GT38 and GT39, derived from human
gastric tissues. The EBV nuclear antigen (EBNA) was detected in all cells of both cell lines. The EBV immediate-early BZLF1 protein
(ZEBRA), the early antigen diffuse component (EA-D), and one of the EBV envelope proteins (gp350/220) were expressed
spontaneously in small proportions in the cells. EBNA1, EBNA2, latent membrane protein 1, ZEBRA, and EA-D molecules were then
observed by Western blotting in the cells. The lytic cycle was enhanced with treatment with 12-O-tetradecanoylphorbol-13-acetate
(TPA) or n-butyrate. The virus particles were observed in the TPA treated GT38 cells by electron microscopy. Infectious EBV was
detected with the transformation of cord blood lymphocytes and also with the induction of early antigen to Raji cells by the
supernatants of both cell lines. A major single and minor multiple fused terminal fragments and a ladder of smaller fragments of
the EBV genome were detected with a XhoI probe in both cell lines. These epithelial cell lines and viruses will be useful in studying
their association with EBV in gastric epithelial cells. © 1998 Academic Press
INTRODUCTION
Epstein–Barr virus (EBV), a causative agent for infectious
mononucleosis and ubiquitous human herpesvirus with
oncogenic potential, is predominantly associated with the
infection of two target tissues in vivo: B lymphocytes, where
the infection is largely nonproductive, and the epithelium, in
which virus replication occurs (Miller, 1990). Both target
tissues are susceptible to EBV-associated malignant
change, leading to tumors of B cell origin, such as Burkitt
lymphoma, or of epithelial cell origin, such as nasopharyn-
geal carcinoma (NPC; Pathmanathan et al., 1995) and gas-
tric carcinoma (Min et al., 1991; Shibata et al., 1991; Shibata
and Weiss, 1992; Tokunaga et al., 1993a, b; Fukayama et al.,
1994; Imai et al., 1994). However, the interaction of EBV with
epithelial cells and the consequent role of the virus in the
etiology of EBV-associated NPC and gastric carcinoma are
poorly understood. One important problem in this study has
been the lack of an epithelial cell culture system in which
EBV is maintained, while the establishment of two EBV-
positive epithelial NPC cell lines has been reported (Glaser
et al., 1989; Yao et al., 1990). CR-2-transfected epithelial
cells have been rendered susceptible to transient EBV
infection in a human epithelial cell system (Li et al., 1992;
Knox et al., 1996). We have recently established two EBV-
infected epithelial cell lines, GT38 and GT39, from gastric
tissues. The characterization of cell lines, including their
epithelial nature, has been described (Tajima et al., 1998).
The present study characterized the mode of EBV infection
and the biological activity of EBV produced in cell lines.
RESULTS
Expression of EBV antigens in GT38 and GT39 cells
The expression of EBV antigens was tested on the cell
lines by immunofluorescence. EBNA was detected in all
GT38 and GT39 cells, although the intensity of fluores-
cence varied from cell to cell (Fig. 1). ZEBRA, EA-D, and
gp350/220 were detected in 3–5% of both cell lines (Fig.
2). Thus these cell lines had spontaneous EBV activation.
The latent proteins, EBNA1, EBNA2, and LMP1, were
detected by immunoblotting in both cell lines (Fig. 3). The
32-kDa ZEBRA polypeptide was detected and EA-D mol-
ecules were observed as two molecules at 54 and 49
kDa in GT38 and GT39 cells (Fig. 4).
Enhancement of EBV production with treatment of
TPA, n-butyrate, and TPA plus n-butyrate
TPA or n-butyrate can induce EBV antigens (zur
Hausen et al., 1978; Luka et al., 1979), and they can act
synergistically in EBV-infected B cells (Sairenji et al.,
1985). The expression of ZEBRA, EA-D, and gp350/220 in
GT38 and GT39 cells was followed by immunofluores-
cence and immunoblotting with each mAb (Fig. 4 and
Table 1). TPA or/and n-butyrate clearly induced the ex-
pression of these antigens. The enhancement of ZEBRA
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and EA-D with TPA was observed by the darker bands of
molecules to the untreated controls (Fig. 4).
EBV particles in GT38 cells
GT38 cells were treated with 20 ng/ml TPA for 3 days
and were examined for the presence of virus particles by
an electron microscope. Virus particles with a morphol-
ogy consistent with that of EBV were found in the nuclei
of the cells (Fig. 5).
Infectious virus on GT38 and GT39 cell lines
The production of the transforming virus was demon-
strated in both cell lines (Table 1). The titers of the trans-
forming virus were 104.5 and 104.0 TD50/ml in GT38 and
GT39 cells, respectively. The production of the virus was
increased 5–10 times in culture fluids of EBV-activated cells
with TPA or TPA plus n-butyrate. It is known that the Jijoye
line originally released transforming EBV, but its clonal cell
line P3HR-1 released a nontransforming, EA-inducing virus
(Sairenji and Hinuma, 1980). EA induction was assayed by
measuring the ability of EA in Raji cells. The titers were
estimated at 104. 6 and 104. 3 EAIU/ml in the culture fluids of
GT38 and GT39 cells, respectively. EA-inducing ability was
blocked by anti-EBV-positive human serum but not by anti-
EBV-negative serum (data not shown). This implies that
these cell lines released the virus, which has a transform-
ing and EA-inducing ability.
Analysis of the terminal restriction enzyme fragments
of EBV DNA
The termini of EBV DNA are involved in various pro-
cesses of the viral life cycle, which consists of a latent
FIG. 1. Immunofluorescence photomicrographs of GT38 and GT39 cells, showing EBNA-positive cells. The nuclear fluorescence was detected in
GT38 (A) and GT39 (C) cells by anti-complement immunofluorescence using an anti-EBNA-positive human serum, but not detected in GT38 (B) and
GT39 (D) using an anti-EBNA-negative human serum.
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and a lytic phase. The clonality of EBV genomes indi-
cated, by extension, cellular monoclonality (Raab-Traub
and Flynn, 1986). To characterize the clonality of EBV
genomes in the cell lines, extracted DNA was digested
with BamHI and hybridized with an EcoRI DIJ het frag-
ment, representing unique DNA adjacent to the right
terminus of EBV as previously described (Hitt et al.,
1989). By short exposure to X- ray films, two major bands
were obtained as expected from episomal EBV DNA in
GT38 and GT39 (Fig. 6A). Hybridization with a XhoI frag-
ment identified a single EBV DNA restriction enzyme
fragment in each of the cell lines, although the sizes
were slightly different (Fig. 6B). The detection of fused
restriction enzyme fragments of EBV termini implied that
GT38 and GT39 may be clonal proliferations of a single
EBV-infected cell, respectively, in agreement with Raab-
Traub and Flynn (1986).
The structure of the EBV termini also provided evi-
dence for virus replication, as indicated by the appear-
ance of ladder arrays of terminal fragments representing
linear forms of EBV DNA (Raab-Traub and Flynn, 1986;
Sato et al., 1988). To identify the linear forms, another
Southern blot was prepared with total intracellular DNA
digested with BamHI from the cell lines. The filter was
hybridized with the XhoI fragment and exposed to a X-ray
film for a long period to detect the terminal fragments of
FIG. 2. Immunofluorescence photomicrographs of lytic antigens. GT38 and GT39 cells were stained with mAbs to ZEBRA (A, D), EA-D (B, E), or
gp350/220 (C, F).
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linear forms (Fig. 7). A ladder of fragments representing
linear termini was detected in sizes from 4.0 to 5.5 kb in
GT38 and GT39 cells and from 4.0 to 6.0 kb in B95-8 cells.
The size of the ladder is consistent with EBV DNA, which
has homologous direct tandem repeats of approximately
500 bp at each terminus (Baer et al., 1984). Major and
minor multiple fused terminal fragments were also iden-
tified with the probe. They ranged in size from 8.1 to 10
and from 8.1 to 12 kb in GT38, GT39, and B95-8 cells,
respectively, while only a single fragment was detected
in Raji cells. The multiple fused terminal fragments and
the ladder of smaller fragments should be related to lytic
forms of viral DNA in GT38, GT39, and B95-8 cells.
Genotype of EBV in GT38 and GT39 cells
The EBV genotype determined by differences in the
sequence of the EBNA2 region was type 1 in both GT38
and GT39 cells (data not shown).
DISCUSSION
In this study, we characterized the expression of EBV
antigens and virus production in GT38 and GT39 epithe-
lial cell lines established from gastric tissues bearing
tumors. The molecules of EBNA1, EBNA2, and LMP1
were detected by Western blotting in both lines. EBV
infection on these lines is referred to as Latency type III,
classified by Rickinson and Kieff (1996). The latency type
III pattern is interesting, because it is characteristic of
the immunoblastic lymphomas of B cell type (i. e., not of
any other tumor) and of EBV-transformed LCL. This type
of EBV infection was different from the infection of EBV-
associated gastric carcinoma cells (Fukayama et al.,
1994; Imai et al., 1994) and of the gastric carcinoma cell
lines infected in vitro with EBV (Yoshiyama et al., 1997),
which detected EBNA1 only but not other latent proteins.
Because EBV latent antigens, except for EBNA1, are
targets of cytotoxic T cells (CTL), cells of Latency type III
may not be able to grow in vivo by the CTL. The Latency
type III in these cell lines needs to be analyzed by the
patterns of EBV latent gene transcription to determine
the uniqueness as described previously (Rickinson and
Kieff, 1996).
TABLE 1
The Expression of EBV Antigens and Production
of Infectious Virus on GT38 and GT39 Cellsa
Cell lines Chemicals
EBV antigens (%)b Infectious virusc
EA-D gp350/220 TD50/ml EAIU/ml
GT38 — 4 2 104.5 104.6
TPA 26 10 105.5 NDd
n-Butyrate 15 4 104.0 ND
TPA 1 n-butyrate 35 13 105.0 ND
GT39 — 3 3 104.0 104.3
TPA 17 9 105.0 ND
n-Butyrate 12 5 104.0 ND
TPA 1 n-butyrate 18 10 104.5 ND
a The cells were treated with TPA (20 ng/ml), n-butyrate (3 mM), or
TPA plus n-butyrate and cultured for 5 days at 37°C.
b The EBV antigens were quantitated by indirect immunofluores-
cence.
c The production of infectious virus was assayed in the culture fluids.
d ND, not determined.
FIG. 3. Western blot analysis of GT38 and GT39 cells, showing the expression of EBNA1 (A), EBNA2 (B), and LMP1 (C). Akata cells were used as
an EBNA1-positive control. B95-8-transformed LCL was used as an EBNA2- and LMP1-positive control. Ramos cells were used as a negative control.
FIG. 4. Western blot analysis of the expression of ZEBRA (A) and
EA-D (B) molecules. GT38 (lanes 1 and 2) and GT39(lanes 3 and 4) cells
were cultured with (lanes 1 and 3) or without (lanes 2 and 4) TPA for 3
days. Anti-IgG-treated Akata (lane 6; Daibata et al., 1992) and Ramos
(lane 5) cells were used as positive and negative controls, respectively.
The same amount (20 mg) of protein was loaded on each lane and
electrophoresed.
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It has been reported that all EBV-carrying gastric car-
cinoma cells have individual single clonotypes of EBV
DNA, as determined by terminal repeat analysis
(Fukayama et al., 1994; Imai et al., 1994). The mono-
clonality of EBV DNA was observed by terminal repeat
analysis in GT38 and GT39 cell lines (Fig. 6). The data
suggest that both GT38 and GT39 cell lines may be
monoclonal in origin, arising from a single EBV-infected
cell. However, we noticed that cell clonality is not simply
determined by the analysis of the terminal repeat of EBV
DNA, if the cells are EBV producers. We demonstrated
not only the ladder of linear forms but also multiple
closed terminal repeats by long exposure to X-ray films,
in GT38, GT39, and B95-8 cells (Fig. 7). Some of the
repeats were increased by TPA treatment and disap-
peared in cellular DNA treated with acyclovir (data not
shown). These bands are very similar to the replication-
dependent forms which were selectively excluded from
covalently closed circular DNA after treatment with acy-
clovir (Sato et al., 1990).
We do not yet know whether GT38 and GT39 cell lines
were derived from EBV-infected carcinoma cells or non-
carcinoma cells of the gastric tissues, althogh these cell
lines macroscopically were established from the non-
cancerous portions of gastric tissues bearing tumors in
two patients (Tajima et al., 1998). PCR analysis of EBNA2
for the typing of EBV demonstrated that the type 1 virus
was infected in both cell lines (data not shown). The type
1 virus was observed in EBV-associated gastric cancers
(Fukayama et al., 1994) and was the predominant type in
the throat washings of normal controls in Japan (Kuni-
moto et al., 1992).
FIG. 5. Electron photomicrograph of GT38 cells treated with TPA for 3 days and observed for virus particles by an electron microscope.
FIG. 6. Clonal analysis of EBV in GT38 and GT39 cells. Cellular DNA
was cleaved with BamHI and the resulting fragments were separated
by electrophoresis and probed with radiolabeled EcoRI DIJ het (A) and
XhoI (B) fragments.
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It is noteworthy that both GT38 and GT39 cell lines are
EBV producers, because only a few cell lines, such as
P3HR-1 (Hinuma et al., 1967) and B95-8 (Miller and Lip-
man, 1973), have previously been known as producers of
B cell lines, although numerous EBV-infected B cell lines
have been established. Infection of epithelial cells in the
oropharynx (Sixbey et al., 1984) and of oral hairy leuko-
plakia (Greenspan et al., 1985) is productive of native
viral progeny. The productive infection of GT38 and GT39
may represent the EBV infection of gastric epithelial
cells, although the infection of gastric carcinoma was
reported to be latent (Imai et al., 1994).
The production of infectious virus was detected by the
transformation of cord blood lymphocytes and by EA
induction in Raji cells with the culture supernatants. This
result suggests that these cell lines produce two biolog-
ically different viruses which have transforming and EA-
inducing activities or a virus that had two different bio-
logical activities. The later type of EBV infection was
observed in NPC-KT cells of a NPC hybrid cell line by
fusing primary NPC epithelial cells with an epithelial cell
line derived from a human adenoid tissue (Takimoto et
al., 1985; Sato et al., 1988). On the other hand, Zhang et
al. reported that only an EA-inducing virus was rescued
from a nasopharyngeal carcinoma epithelial tumor cell
line by treatment with iododeoxyuridine (Zhang et al.,
1990). No cell line which produces a transforming and
EA-inducing virus has been reported in B cell lines,
although the P3HR-1 cell line produces EA-inducing vi-
rus and the parental Jijoye line is known to produce a
transforming virus (Sairenji and Hinuma, 1980). There-
fore, the strains of EBV on GT38 and GT39 cell lines
appear to be unique in that they have transforming and
EA-inducing properties.
The latency of EBV in GT38 and GT39 cells was acti-
vatied by TPA or n-butyrate. However, TPA with EBV
activation is more efficient than n-butyrate (Table 1). This
was different from B cell lines, in which the EBV activa-
tion was induced more efficiently by n-butyrate than TPA
(Sairenji et al., 1985). The EBV lytic cycle is initiated on
the expression of the BZLF1 gene product ZEBRA (also
called EB1, Zta) in B cells (Miller, 1990). On the other
hand, EBV latency was disrupted by another immediate-
early BRLF1 protein in epithelial cells (Zalani et al., 1996).
The observed differences between TPA and n-butyrate
may reflect the mechanisms leading to the disruption of
EBV latency in B cells and epithelial cells.
We isolated EBV strains from gastric epithelial cells.
These viruses could serve as new prototype viruses
derived from gastric epithelial cells and as in vitro mod-
els for studying the system of EBV infection to epithelial
cells and the association between EBV and gastric car-
cinoma.
MATERIALS AND METHODS
Cell cultures
The cells were maintained in RPMI 1640 medium con-
taining 10% fetal calf serum, 100 U/ml penicillin, and 100
mg/ml streptomycin. The cells were treated with 0.25%
trypsin and 100 mM EDTA and passaged at intervals of 4
to 6 days. For EBV activation, cells were treated with 20
ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma
Chemical Co., St. Louis, MO), 3 mM n-butyrate (Sigma),
or both for indicated days at 37°C. EBV genome-positive
Raji (Pulvertaft, 1965) and Akata (Takada and Ono, 1989)
cells, a lymphoblastoid cell line (LCL) transformed by the
B95-8 virus (Miller and Lipman, 1973), and EBV genome-
negative Ramos (Klein et al., 1975) cells were used.
Immunofluorescence
Cells were fixed in acetone–methanol (2:1) and
stained for EBV nuclear antigen (EBNA) by anti-comple-
ment immunofluorescence using an EBNA antibody-pos-
itive or a negative human serum and fluorescein isothio-
cyanate (FITC)-conjugated goat IgG fraction to human
complement C3 as described previously (Reedman and
Klein, 1973). The detection of BamHI Z EBV replication
activator (ZEBRA), the BMRF1 early antigen diffuse com-
ponent (EA-D), and one of the envelope components
(gp350/220) was performed by indirect immunofluores-
cence using the mAbs to ZEBRA (developed in our lab-
oratory), EA-D (DuPont, Wilmington, DE), and gp350/220
(Thorley - Lawson and Geilinger 1980) and FITC-labeled
anti-mouse IgG.
FIG. 7. Variation of numbers of EBV terminal repeats in GT38
and GT39 cells. The Southern blot was prepared from the intra-
cellular DNAs, digested with BamHI, and hybridized with the radio-
labeled XhoI fragment and exposed at length to a X-ray film to reveal
the full possible range of copies of EBV terminal repeats of linear
form. The major terminal repeat of covalently closed circular DNA
() and the linear form of terminal repeats () are shown.
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Immunoblotting
To analyze the expression of EBV proteins, the cell
extracts were subjected to sodium dodecyl sulfate (SDS)–
polyacrylamide gel electrophoresis (PAGE) and trans-
ferred onto Immobilon-P membranes (Millipore Co., Bed-
ford, MA). The proteins were proved with mAbs specific
to EBNA1 (Oncogene Res. Prod., MA), EBNA2 (DAKO
Japan Co., Ltd, Kyoto, Japan), LMP1 (DAKO), ZEBRA (de-
veloped in our laboratory), and EA-D (DuPont).
Assay of virus infectivity
The infectious virus in culture fluids was assayed by
measuring the ability of the virus to transform cord lym-
phocytes as described previously (Sairenji and Hinuma,
1980). To 50 ml cell suspension (2 3 106 cells/ml) of cord
blood lymphocytes in a 96-well plate, 50 ml of a 10-fold-
diluted culture supernatant was added and cultured at
37°C in a CO2 incubator. Half of the volume of the
medium was changed every 4 or 5 days. Transformation
was judged by morphological change (lymphoblastoid
appearance, clumping of cells, acid production). The titer
was estimated as 50% transforming doses (TD50)/ml
based 50% transformation end point of cord lymphocytes
by the Reed and Muench method (Sairenji and Hinuma,
1980). EA induction was assayed by measuring the abil-
ity to induce EA in the superinfection of Raji cells and
described by the EA-inducing unit (EAIU)/ml as de-
scribed previously (Sairenji and Hinuma, 1973).
Electron microscopy
The electron microscopic procedure was done with
thin sections as described previously (Katsumoto et al.,
1981). Briefly, cells were cultured on a plastic sheet,
which is a disk of 23 mmf (Wako Pure Chemical Indus-
tries, Ltd., Osaka, Japan) in a 35-mm dish and treated
with 20 ng/ml TPA for 3 days. The cells were washed with
PBS and postfixed with 2.5% glutaraldehyde and 1%
OSO4 in PBS. These samples were dehydrated with eth-
anol and embedded in epoxy resin. Sections of 80 nm
thickness were prepared, stained with uranyl acetate
and lead citrate, and then observed under a Hitachi
H-7100 electron microscope operated at 75 kV.
Analysis of EBV DNA
To analyze the clonality of EBV genomes in cells,
Southern blotting was done for the fused termini of EBV
in cells with 32P-labeled EcoRI DIJ het (Dambaugh and
Kieff, 1982; Hitt et al., 1989) or XhoI probes, as described
previously (Raab-Traub and Flynn, 1986).
For EBV typing, the first PCR was performed with the
common EBNA2 primers. The 5 ml of the first reaction
product was transferred to the nested reaction tubes
containing EBV-1 and EBV-2 type-specific primers
(Telenti et al., 1991). The amplified products were elec-
trophoresed in 2% agarose gel and detected by ethidium
bromide as described previously (Takasaka et al., 1996).
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